The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
 
Kevin J. Harrington
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Research Funding - AstraZeneca; MSD
 
Martin David Forster
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Lilly; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly; Merck; MSD; Pfizer
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Merck Serono; MSD; Nanobiotix
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Jose Ariza
No Relationships to Disclose
 
Shuquan Chen
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Jonathan Greenberg
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Research Funding - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Kenji Hirotani
Employment - Daiichi Sankyo
 
Eva Remenar
No Relationships to Disclose